Metrosa (Metronidazole)

Metronidazole is taken up by susceptible microorganisms and undergoes reduction of its nitro group. This process creates reactive radicals that damage DNA and inhibit nucleic acid synthesis, leading to microbial cell death and reduction of inflammation in the treated area.

The dosage of Metrosa is determined by the prescribing clinician based on the severity of the skin condition, patient age, and tolerance. The prescriber will specify the amount to apply, frequency, and duration of therapy on the product label.

Safety data for topical metronidazole in pregnancy are limited, so use only if the potential benefit outweighs any risk and after consulting a healthcare professional. While small amounts may be excreted in breast milk, caution is advised and a prescriber should evaluate the need for treatment while breastfeeding.

To order Metrosa, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metrosa (topical metronidazole) offers anti‑inflammatory and antimicrobial activity, making it useful for rosacea and mild‑to‑moderate acne. Compared with topical clindamycin, metronidazole has a lower risk of antibiotic resistance. Oral tetracyclines provide systemic action but carry higher systemic side‑effect profiles. Choice depends on disease severity, patient preference and physician assessment.

Metrosa should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keep the container tightly closed when not in use and out of reach of children. Do not freeze or expose the product to excessive heat.

Metrosa is applied topically to clean, dry skin. The prescriber will advise the amount (usually a thin film) and frequency, commonly twice daily. It should be spread gently over the affected area and allowed to absorb before applying other skin products.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and rare systemic neurotoxicity if significant absorption occurs. Patients should seek immediate medical attention if they experience swelling, blistering, widespread rash, or neurological symptoms.

Metrosa should not be used by individuals with known hypersensitivity to metronidazole or any component of the formulation. It is also contraindicated on severely broken skin, in patients with G6PD deficiency who may develop hemolysis, and in those where a prescriber determines the risks outweigh the benefits.